New Clinical Muedzo weProstate Cancer Treatment

rakanyorwa mupepeti

Hinova Pharmaceuticals Inc., kambani yekiriniki-nhanho biopharmaceutical yakanangana nekugadzira zvinyorwa zvekurapa kwegomarara uye zvirwere zvemetabolism kuburikidza neakatariswa mapuroteni ekuderedza matekinoroji, yakazivisa kuti murwere wekutanga ane metastatic castration-resistant cancer yeprostate (mCRPC) yakabudirira kudhonzwa muchikamu chekutanga. kliniki kuyedzwa kweHP518, yakasarudzika uye nemuromo bioavailable chimeric degrader yakanangana neandrogen receptor (AR). Iyo inoenderera yakavhurika-label Phase I kudzidza muAustralia ichaongorora kuchengetedzeka, pharmacokinetics, uye anti-bundu chiitiko cheHP518 muvarwere vane mCRPC.

Print Friendly, PDF & Email

HP518 yakawanikwa uye yakagadziridzwa neHinova yakanangwa protein degradation drug discovery chikuva. Iyo ine mukana wekukunda kushomeka kwemishonga yekenza yeprostate nekuda kwekumwe kuchinjika kweAR.

Chimeric degraders ane bifunctional mamorekuru madiki anokurudzira kushatiswa kwechinangwa cheprotein ane potency yakakura uye yakakwirira kusarudza. Tekinoroji iyi ine mukana wekunangisa zvibodzwa zvisingadhurike uye kukunda nyaya yekuramba mishonga yemishonga midiki yemamorekuru.

"Ichi chiitiko chakakosha mukufambira mberi kwekuedza kwedu kubva mukuwanikwa kwezvinodhaka kusvika kuongororo yekiriniki," akadaro Yuanwei Chen, Ph.D., Mutungamiriri uye CEO weHinova. "Tinofara nazvo uye takazvipira kuunza nzira nyowani dzekurapa kuvarwere pasi rese!"

Kuburikidza neyakanangwa yeprotein degradation zvinodhaka zvekuwanikwa papuratifomu, Hinova inogona kuongorora mapuroteni ekuderedza chiitiko nekukurumidza uye kuita dhizaini inoshanda uye optimization yezvimeric zvinosvibisa. Uyezve, Hinova ane ruzivo rwakadzama mukugadzirwa kwemakemikari kutonga kweChimeric degrader compounds.

Print Friendly, PDF & Email

Nezvomunyori

mupepeti

Mupepeti mukuru we eTurboNew ndiLinda Hohnholz. Iye anogara muTN HQ muHonolulu, Hawaii.

Leave a Comment